(News Bulletin 247) – The Spanish biopharmaceutical group Almirall rose slightly on the stock market on Monday after maintaining its annual objectives and despite a drop in its operating profit in the first quarter due to the loss of income linked to an agreement with AstraZeneca.
The laboratory announced this morning that it generated net sales up 6% to 232 million euros over the first three months of the year, thanks to the dynamism of its dermatological portfolio, its new core business.
Its gross operating income (EBITDA) nevertheless fell by 13.1% to 51.8 million euros, the attention paid to dermatology having also resulted in a decline in sales of its other drugs ( antihistamines, anti-migraine, etc.).
Its general and administrative costs also increased by 3.7% during the quarter, to reach 106.7 million euros, due to the preparation of the market launches of Wynzora (psoriasis) and Klisyri (actinic keratosis) in the United States and Europe and the rise of Ilumetri (psoriasis), its bestseller.
After this good start to the year, Almirall confirmed its objectives for 2023, which foresee net sales increasing by 0% to 5% for an Ebitda of between 165 and 180 million euros.
Founded in 1943 in Barcelona, ​​Almirall today employs 1,800 people in some twenty countries.
Shortly before 12:00 p.m., its title advanced 1.1% on the Madrid Stock Exchange,
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
